Pfizer’s Waxman to Leave

Pfizer’s Waxman to Leave
Remains Outside Counsel Through Transition Period

NEW YORK--(BUSINESS WIRE)--Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel to Pfizer through a transition period.

Pfizer said David Reid, currently Senior Vice President and Managing Director, will assume Mr. Waxman’s responsibilities on an interim basis while the company conducts a search for a permanent successor.

“Allen and his team have been strong advocates for Pfizer, securing a number of important legal decisions that are significant for our business and our future,” said Jeff Kindler, Chairman and Chief Executive Officer. “Allen has provided valuable counsel not only on legal matters but on our overall business strategy and the issues facing Pfizer in its operating environment. He has made many contributions to our company. We thank him for those contributions and wish him well in his future endeavors.”

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.